Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis
Kaneez Fatima, Abdul Moeed, Eisha Waqar, et al.
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101816-101816
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 83
Pravastatin reduces all-cause mortality in elderly at risk of liver fibrosis: post-hoc analysis of the PROSPER trial
Vivian D. de Jong, Willy Theel, Manuel Castro Cabezas, et al.
JHEP Reports (2025), pp. 101337-101337
Open Access | Times Cited: 1
Metabolic dysfunction-associated steatotic liver disease and the heart
Stan Driessen, Sven Francque, Stefan D. Anker, et al.
Hepatology (2023)
Open Access | Times Cited: 27
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 12
Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios A. Anastasilakis, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2195-2206
Closed Access | Times Cited: 30
Advanced effect of curcumin and resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K/AKT/mTOR and HIF-1/VEGF cascade
Yuhui He, Huan Wang, Shiling Lin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115279-115279
Open Access | Times Cited: 18
Effect of statin use on liver enzymes and lipid profile in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Anh Ho, Takako Kiener, Quynh‐Nhu Nguyen, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 4, pp. e501-e508
Open Access | Times Cited: 5
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease
Kosmas I. Paraskevas, Péter Gloviczki, Pier Luigi Antignani, et al.
Progress in Cardiovascular Diseases (2022) Vol. 73, pp. 41-47
Open Access | Times Cited: 23
Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Thaninee Prasoppokakorn
Livers (2025) Vol. 5, Iss. 1, pp. 4-4
Open Access
Steatotic Liver Disease: Navigating Pathologic Features, Diagnostic Challenges, and Emerging Insights
Jingjing Jiao, Xuchen Zhang
Advances in Anatomic Pathology (2025)
Closed Access
Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025), pp. 103209-103209
Closed Access
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
José A. Inia, Geurt Stokman, Elsbet J. Pieterman, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7818-7818
Open Access | Times Cited: 12
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2232-2244
Closed Access | Times Cited: 11
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Woon Chang, Pil Soo Sung, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 3, pp. 425-472
Open Access | Times Cited: 17
Anti-fibrotic effects of statin drugs: A review of evidence and mechanisms
David Dolivo, Charlotte R. Reed, Kristine A. Gargiulo, et al.
Biochemical Pharmacology (2023) Vol. 214, pp. 115644-115644
Closed Access | Times Cited: 10
Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis
Xingfen Zhang, Dandi Lou, Rongrong Fu, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 6, pp. 762-775
Open Access | Times Cited: 9
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
George Agyapong, Farzaneh Dashti, Bubu A. Banini
Annals of the New York Academy of Sciences (2023) Vol. 1526, Iss. 1, pp. 16-29
Open Access | Times Cited: 9
Onion Polyphenols as Multi-Target-Directed Ligands in MASLD – a Preliminary Molecular Docking Study
Maria Rosaria Paravati, Anna Caterina Procopio, Maja Milanović, et al.
(2024)
Open Access | Times Cited: 3
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
Simona Cernea, Danusia Onișor
World Journal of Gastroenterology (2023) Vol. 29, Iss. 2, pp. 286-309
Open Access | Times Cited: 8
Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta‐analysis of randomized controlled trials
Ali Ardekani, Reza Tabrizi, Elham Maleki, et al.
Food Science & Nutrition (2023) Vol. 11, Iss. 6, pp. 2580-2588
Open Access | Times Cited: 7
Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study
Maria Rosaria Paravati, Anna Caterina Procopio, Maja Milanović, et al.
Nutrients (2024) Vol. 16, Iss. 8, pp. 1226-1226
Open Access | Times Cited: 2
Potential therapeutic strategies for MASH: from preclinical to clinical development
Zhifu Xie, Yufeng Li, Long Cheng, et al.
Life Metabolism (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 2
Wulingsan Alleviates MAFLD by Activating Autophagy via Regulating the AMPK/mTOR/ULK1 Signaling Pathway
Yaning Biao, D. Li, Yixin Zhang, et al.
Canadian Journal of Gastroenterology and Hepatology (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 2
Statin use and development and progression of non-alcohol fatty liver disease based on ultrasonography: a cohort study
Baoyu Feng, Fengde Li, Yanqi Lan, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top